Pulse Biosciences reported significant progress in its market development programs and positive clinical outcomes, particularly in soft tissue ablation and cardiac device development. However, the company faces rising operating expenses and net losses, along with expected increases in cash use. Despite these challenges, the company's strong cash position and upcoming revenue generation provide a positive outlook.

Company Guidance

During the Pulse Biosciences Second Quarter 2025 Earnings Conference Call, the company provided guidance on its progress and future plans. The CEO, Paul LaViolette, announced significant advancements in their Nanosecond Pulsed-Field Ablation (nsPFA) technology, highlighting its application in soft tissue ablation and cardiac procedures. The company has expanded pilot utilization for benign thyroid disease and submitted two Investigational Device Exemption (IDE) applications for atrial fibrillation treatment and a cardiac surgical clamp. Over 140 patients have been treated with their percutaneous electrode system, with a focus on transitioning procedures to ambulatory surgery centers for optimal patient access and reimbursement. Financially, the second quarter saw GAAP costs and expenses rise to $20.3 million, primarily due to expanded organizational efforts, with a GAAP net loss of $19.2 million. The company ended the quarter with $106.3 million in cash and plans to increase cash use in the second half of 2025 as they invest in commercial infrastructure and clinical studies. Initial revenue from the percutaneous electrode is anticipated later in the year, with the company exploring various purchase models to suit customer needs.

Progress in Market Development Programs

Pulse Biosciences is advancing its nsPFA technology in three market development programs, with expanded pilot utilization and positive clinical results in Europe. The company has submitted two IDEs for regulatory goals.

Soft Tissue Ablation Success

The nsPFA percutaneous electrode system is FDA cleared for the ablation of soft tissue, with over 140 patients treated in a pilot program and positive outcomes reported. It offers a minimally invasive alternative to thyroidectomy.

Cardiac Surgical Clamp Advancements

The nsPFA surgical ablation clamp has received Breakthrough Device designation and is in the FDA's TAP program. A pivotal trial is planned with 150 patients, supported by positive clinical outcomes from European studies.

Financial Strength

As of June 30, 2025, cash and cash equivalents totaled $106.3 million, up from $26.2 million a year ago. Expected revenue generation from the percutaneous electrode in the second half of 2025.

Cardiac Catheter Feasibility Study

Over 140 patients treated in Europe with positive outcomes. The 360 cardiac catheter system demonstrates decreased procedure times and compatibility with major mapping systems.

Pulse Biosciences (PLSE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PLSE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.31 / -	-0.156	―	―	―
Aug 12, 2025	2025 (Q2)	-0.26 / -0.20	-0.2	0.50% (<+0.01)	―
May 08, 2025	2025 (Q1)	- / -0.17	-0.143	-18.88% (-0.03)	―
Mar 27, 2025	2024 (Q4)	- / -0.17	-0.154	-7.14% (-0.01)	―
Oct 30, 2024	2024 (Q3)	- / -0.16	-0.152	-2.63% (>-0.01)	―
Aug 12, 2024	2024 (Q2)	- / -0.20	-0.22	9.09% (+0.02)	―
May 07, 2024	2024 (Q1)	- / -0.14	-0.227	37.00% (+0.08)	―
Mar 28, 2024	2023 (Q4)	- / -0.15	-0.221	30.32% (+0.07)	―
Nov 13, 2023	2023 (Q3)	-0.24 / -0.15	-0.456	66.67% (+0.30)	―
Aug 10, 2023	2023 (Q2)	-0.24 / -0.22	-0.374	41.18% (+0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PLSE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$15.10	$16.79	+11.19%
May 08, 2025	$16.85	$17.07	+1.31%
Mar 27, 2025	$15.66	$16.60	+6.00%
Oct 30, 2024	$17.72	$17.43	-1.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pulse Biosciences (PLSE) report earnings?

Pulse Biosciences (PLSE) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Pulse Biosciences (PLSE) earnings time?

Pulse Biosciences (PLSE) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PLSE EPS forecast?

PLSE EPS forecast for the fiscal quarter 2025 (Q3) is -0.31.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing